Price Target Analysis of ChromaDex Corporation (CDXC)

Bank of America Merrill Lynch

ChromaDex Corporation (CDXC) belonging to the Medical sector has surged 3.22% and closed its last trading session at $3.21.

The company reported its EPS on 03/16/2017. Currently, the stock has a 1 Year Price Target of $6.

The consensus recommendation, according to Zacks Investment research, is 1. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell.

The Stock had a 1 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 1 and 1 respectively.

ChromaDex Corporation on 03/16/2017 reported its EPS as $-0.05 with the analysts projecting the EPS of the stock as $-0.01. The company beat the analyst EPS Estimate with the difference of $-0.04. This shows a surprise factor of -400%.

Many analysts have provided their estimated foresights on ChromaDex Corporation Earnings, with 1 analysts believing the company would generate an Average Estimate of $0.01.

Whereas they predicted High and Low Earnings Estimate as $0.01 and $0.01 respectively.

Analysts are also projecting an Average Revenue Estimate for ChromaDex Corporation as $1000 in the Current Quarter. This estimate is provided by 8000 analysts.

Insider Trades for ChromaDex Corporation show that the latest trade was made on 19 Mar 2017 where Allen Stephen R, the Director completed a transaction type “Buy” in which 2000 shares were traded at a price of $2.81.

ChromaDex Corporation (CDXC) has the market capitalization of $115.82 Million. The company rocked its 52-Week High of $3.95 and touched its 52-Week Low of $2.25.

The stock has Return on Assets (ROA) of -16.1 percent. Return on Equity (ROE) stands at -28.8% and Return on Investment (ROI) of -24.1 percent.

The stock is currently showing YTD performance of -3.02 Percent. The company has Beta Value of 1.06 and ATR value of 0.2. The Weekly and Monthly Volatility stands at 10.46% and 6.44%.